The purpose of this summary is to explain key findings from a study that included people with schizophrenia, as described in two separate articles (see the 'Further Information' section for more details). The study compared a new formulation of aripiprazole, given as an injection once every 2 months, with a once‑monthly injection of aripiprazole.
Keywords: Antipsychotic; Aripiprazole; Long-acting injectable; Schizophrenia.
© The Author(s), 2024.